these studies for today's clinical practice is uncertain because they predated the HAART era, had a limited duration of followup, or included only a few patients undergoing HAART.
If HRQL would independently predict mortality, physicians could consider HRQL in conjunction with clinical parameters when assessing the prognosis of HIV-infected patients. The aim of the present study was to investigate whether HRQL predicts survival in the national AIDS Therapy Evaluation in the Netherlands (ATHENA) cohort, which consists of HIV-infected patients receiving HAART with a long follow-up time.
METHODS

Participants.
Patients participated in the Dutch national observational cohort ATHENA. This cohort encompasses all patients known to be infected with HIV-1 in the Netherlands who are followed up at 1 of 22 treatment centers that provide HIV care. Epidemiologic, clinical, virologic, and immunologic data are collected retrospectively at entry into the cohort and prospectively thereafter. Initially, ATHENA only enrolled adults infected with HIV-1 who were either starting or already using antiretroviral therapy with at least 1 of the drugs that were licensed in the Netherlands from 1 July 1996 onward (ie, all protease inhibitors [PIs] and nonnucleoside reverse transcriptase inhibitors [NNRTIs] , lamivudine, and stavudine). For the current study, HAART was defined as a combination of at least 3 drugs from at least 2 classes or a combination of 3 or more nucleoside reverse transcriptase inhibitors (NRTIs), including abacavir or tenofovir. Further details about the ATHENA cohort are described elsewhere [9, 10] .
In a subset of the entire ATHENA population, the ATHENA focus group ( ), which consists of patients receiving N p 584 HAART or starting HAART with sufficient literacy in Dutch or English to complete self-report questionnaires, HRQL questionnaires were administered from 1 May 1998 through 31 December 2000. A total of 570 patients (response rate, 97.6%) gave informed consent for participation and completed a questionnaire. For 10 patients no end point was registered in ATHENA; therefore, the present study reports on 560 patients.
HRQL. HRQL was measured using the Medical Outcomes Study HIV (MOS-HIV) Health Survey. The MOS-HIV Health Survey contains 10 subscales from which physical health summary (PHS) and a mental health summary (MHS) scores can be calculated. The subscales of physical functioning, pain, role functioning, social functioning, and health perceptions contribute most to the PHS. The subscales of mental health, health distress, overall quality of life, cognitive functioning, and vitality contribute most to the MHS [11] . All scales and summary scores ranged from 0 to 100, with higher scores indicating better HRQL and lower scores indicating worse HRQL. Summary scores are standardized to a population mean ‫ע(‬ standard deviation) of 50 ‫ע‬ 10 [11] . The MOS-HIV Health Survey subscales and the PHS and MHS yield high levels of reliability and validity [11] [12] [13] .
Survival. The end point of the study was all-cause mortality. A distinction in causes of death was made using the categorization of the Coding of Death in HIV Project [14] . Mortality was registered by the treating physician or counselor of the patient concerned. We established this end point at 31 March 2008 when we closed the database for the current analyses. Of 10 patients (1.8%), no end point was registered.
We calculated survival time from the date of completion of the HRQL questionnaire. Time was censored at the end of follow-up, which was the last contact with the hospital or time of death, whichever occurred first.
Demographic and clinical parameters. We considered the following demographic and clinical characteristics at study entry for their prediction on survival: sex, age, country of birth, HIV transmission route, having had a C-class event according to the 1993 Centers for Disease Control and Prevention's definition and categorization of HIV-1-related events [15] , CD4 cell count and plasma HIV-1 RNA concentration at study entry and at start of HAART, having had treatment with antiretroviral drugs before the start of HAART, type of antiretroviral regimen, and number of years undergoing HAART (Table 1 ). Viral load was considered undetectable when the plasma HIV-1 RNA concentration was !500 copies/mL. We distinguished the following antiretroviral regimens: HAART containing a single PI, a ritonavir-boosted PI, an NNRTI, or an NNRTI plus a PI and non-HAART regimens.
Statistical analyses. We calculated the median PHS and MHS scores. The PHS and MHS scores had a skewed distribution toward most patients who reported a relatively good HRQL. Therefore, we divided the PHS and MHS into quartiles, with quartile 1 indicating worst HRQL and quartile 4 indicating best HRQL.
We conducted x 2 tests to investigate differences in the percentage of patients who died. Survival curves by quartiles of PHS and MHS scores were estimated by the Kaplan-Meier method. Differences in survival by quartile of PHS and MHS scores were tested using log-rank tests. We used Cox proportional hazards regression models to evaluate the prediction of PHS, MHS, and clinical and demographic variables on survival. For these analyses, PHS and MHS were included as continuous variables. The calculated hazard rate (HR) depicts the risk of death.
We explored the prediction of the 10 subscales on survival bivariately to obtain more insight into the contribution of the subscales. The PHS and MHS scores could not be calculated when subscale scores were missing. The prediction of missing the summary scores or subscales on survival was calculated using Cox proportional hazards regression models.
All variables that were bivariately associated with survival ( ) were introduced into a multivariate Cox regression P ! .25 model using backwards stepwise analysis. Variables were kept in the model when significantly associated with survival (P ! ). Schoenfeld tests of residuals were conducted to examine .05 whether the proportional hazards assumption was met (P ! ). . 05 In patients who died we explored post hoc whether there was a difference in PHS and MHS scores among the different causes of death, using the Wilcoxon rank sum test ( ). P ! .05 We used SAS statistical software, version 9.1 (SAS Institute) for analyses.
RESULTS
Participants.
Characteristics of patients at study entry are presented in Table 1 ). Of patients who had no summary scores, 8 (23%) P p .52 died. We observed no differences in characteristics at study entry between patients with missing summary scores compared with patients with complete data. Figure 1 and Figure 2 display the Kaplan-Meier curves for patients in the different quartiles of PHS and MHS scores, including those who had no summary scores. A significant difference in survival was found among the quartiles of patients with a PHS score ( ) but not P ! .001 among the quartiles of patients with an MHS score ( ). P p .13 Twenty-two patients (33%) died of AIDS-related diseases, such as malignant tumors and infections, 12 (18%) of heart and lung conditions, 11 (17%) of non-AIDS-related malignant tumors, 6 (9%) of liver and pancreas conditions, 6 (9%) of suicide, accidents, or euthanasia, 4 (6%) of non-AIDS-related infections, and 5 (8%) of unknown conditions. There was no clear pattern of differences in PHS and MHS scores among the different causes of death.
Predictors of survival. 
DISCUSSION
Patient-reported HRQL was a significant and independent predictor of survival among HIV-infected patients receiving HAART, with a median follow-up time of 8.4 years in the ATHENA cohort. The physical component of HRQL remained a significant predictor even after adjustment for demographic and clinical factors. Our findings suggest that HRQL could be used to assess the prognosis among HIV-infected patients in conjunction with demographic and clinical variables. These results might be of interest to both resource-rich and resourcepoor countries.
The finding that HRQL predicts survival adds to evidence from other studies. A number of explanations have been proposed for why self-reported HRQL predicts survival over and above established demographic and clinical prognostic factors [3] . First, self-reported health status may capture the entire range of symptoms, including subtle signs of disease progression a person perceives. Second, whereas perceptions of poor health might lead to behaviors that positively influence health status, they predominantly have been found to induce behaviors that negatively influence health status, such as lesser involvement in preventive activities or self-care and nonadherence to screening recommendations, medication, and treatment. In addition, health perceptions may be influenced by resources in the external social environment, such as income and social networks, and within-person resources, such as control over health. Therefore, self-rated health is believed to reflect both perceptions and subsequent behaviors and resources [3] .
It seems plausible that self-reported HRQL may influence survival in HIV infection, at least in part, via adherence to HAART. The association between suboptimal adherence to HAART and an increased risk of mortality is well documented [3] . There is only limited evidence on the relation between HRQL and subsequent adherence, with inconsistent results [16] [17] [18] . Several studies have established a relationship between a poorer self-reported mental health or a higher number of depressive symptoms and an increased risk of HIV disease progression and/or mortality [19] [20] [21] [22] . Self-reported depressive symptoms have been found to affect survival both directly and via adherence [7, [19] [20] [21] [22] . Our finding that the PHS but not the MHS predicted survival is therefore unexpected. Moreover, the subscales expected to measure depression to some extent (ie, mental health, health distress, quality of life, cognitive func- ). n p 560 tion, and vitality) were not predictive of survival. Our finding that the PHS but not the MHS predicted survival is consistent with 3 previous studies among HIV-infected patients that predate the HAART era or include only a few patients receiving HAART [6, 7, 23] .
The subscales that were most predictive of survival were physical functioning, pain, role functioning, and social functioning. These subscales contribute to PHS and focus predominantly on limitations in usual daily activities, such as walking the stairs or carrying groceries. Self-reported PHS seems to be an inclusive and robust measure of health, reflecting health aspects relevant to survival that are not covered by common clinical indicators that we investigated in the present study. One could speculate that future studies might explore the possibility of stratifying patients on the basis of their baseline HRQL in clinical trials in which survival is an end point. Although PHS was independently predictive of survival, this does not imply a causal relationship. The mechanism by which self-reported HRQL influences survival remains to be determined [24] . Also, the post hoc analyses regarding causes of death did not reveal information about the mechanism because causes of death were too diverse and patient numbers were too small. Future research should determine the prognostic value of HRQL on survival in clinical settings. If this prognostic value would be established, it might be useful to provide patients with the prognostic HRQL information to encourage greater adherence.
An interesting finding is that failure to complete all items of the questionnaire, resulting in missing summary scores, was associated with an increased risk of mortality. Failure of completion might be due to fatigue or concentration problems and thereby indicative of a poor health status. In particular, failure to complete items about cognitive functioning increased the risk of mortality (HR, 120; ). These items focus on P ! .001 difficulties with reasoning and solving problems, forgetfulness, trouble paying attention, and difficulties with concentration and thinking. ). n p 560
Our study has several limitations. A percentage of our patients were already receiving HAART when they enrolled in ATHENA and completed the HRQL questionnaire. Ideally, we would have assessed HRQL in all patients at the start of HAART. Restricting our analysis to patients initiating HAART at enrollment in ATHENA would have reduced our sample size substantially. By investigating the effect on survival of the pre-HAART HIV RNA concentration, the pre-HAART CD4 cell count, and the use of antiretroviral treatment before starting HAART, we attempted to adjust for this limitation. In addition, we analyzed the prediction of HRQL on survival among those who were treatment naive at the start of this study (not displayed in results). The outcomes showed the same trend (PHS: HR for each 5 points, !1) as in the entire group but were not significant because of small numbers.
Inherent with the long follow-up period of our study, the HAART regimens do not reflect HAART regimens that are currently used. Current HAART regimens are more effective and often better tolerated and easier to take than those prescribed at the start of our study. Possibly, this may influence the association between self-reported HRQL and survival, because these newer regimens might have an effect on both HRQL and survival. However, knowing the relationship between HRQL and survival in patients following those HAART regimens remains of relevance because these patients still form a large percentage of today's population of HIV patients. Moreover, the HAART regimens used in the study period are still used in resource-poor settings.
Also inherent in our prolonged follow-up period is the homogeneous composition of our study population. Our study population mainly consisted of men having sex with men (76.1%), which reflects the composition of the HIV-infected population in the Netherlands at that time. Currently, heterosexuals, especially patients from ethnic minority groups, constitute a larger part of the HIV-infected population in the Netherlands [10] . Nevertheless, men having sex with men still form a substantial part of the population of HIV-positive patients. We therefore believe that our finding that HRQL predicts survival in this group is important. In line with the composition of the study population is the lack of data on other possible confounders, such as socioeconomic status and access to health care. Both have been found to strongly predict mortality. However, we think these factors might play a minor role in our study because the study sample consists of a homogenous group with an above average socioeconomic status. Also, in the Netherlands nearly everyone has health insurance and therefore access to health care. Future studies should corroborate our findings among other groups of patients and include measurement of other confounders that might predict survival, such as socioeconomic status.
We choose the MOS-HIV Health Survey for our study because it is the most widely used measure of HRQL in HIVinfected patients and has good reliability, validity, and responsiveness [11] [12] [13] . We previously demonstrated good reliability and validity of a Dutch version of the MOS-HIV Health Survey [25] . A potential limitation of the MOS-HIV Health Survey is a low sensitivity because it is a rather generic measure of HRQL. Nevertheless, the MOS-HIV Health Survey was a significant predictor of survival in the present study.
The most important strength of our study is the long followup period of more than 8 years, giving insight into the prediction in the long term. Other strengths include a large sample size, embedment of our HRQL study within the ATHENA cohort, which assesses a larger range of clinical measures than existing studies, and use of the clinically relevant and unambiguous end point all-cause mortality.
In summary, physical HRQL predicts survival in the long term in a population of HIV-infected patients receiving HAART independent of demographic and clinical variables. Future research should determine the prognostic value of HRQL on survival in clinical settings. Also, the mechanism by which physical HRQL influences survival remains to be determined. Potentially, this information could be highly useful for physicians in assessing the prognosis of their patients in resource-rich and resource-poor countries. 
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